Nitrilase mediated mild hydrolysis of a carbon-14 nitrile for the radiosynthesis of 4-(7-hydroxycarbamoyl-[1-14C-heptanoyl]-oxy)-benzoic acid methyl ester, [14C]-SHP-141: A novel class I/II histone deacetylase (HDAC) inhibitor

IF 0.9 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Journal of labelled compounds & radiopharmaceuticals Pub Date : 2023-04-25 DOI:10.1002/jlcr.4026
Sean L. Kitson, William Watters, Thomas S. Moody, Todd Chappell, Ralph Mazitschek
{"title":"Nitrilase mediated mild hydrolysis of a carbon-14 nitrile for the radiosynthesis of 4-(7-hydroxycarbamoyl-[1-14C-heptanoyl]-oxy)-benzoic acid methyl ester, [14C]-SHP-141: A novel class I/II histone deacetylase (HDAC) inhibitor","authors":"Sean L. Kitson,&nbsp;William Watters,&nbsp;Thomas S. Moody,&nbsp;Todd Chappell,&nbsp;Ralph Mazitschek","doi":"10.1002/jlcr.4026","DOIUrl":null,"url":null,"abstract":"<p>A strategy has been developed for the carbon-14 radiosynthesis of <b>[</b><sup><b>14</b></sup><b>C]-SHP-141</b>, a 4-(7-hydroxycarbamoyl-heptanoyloxy)-benzoic acid methyl ester derivative containing a terminal hydroxamic acid. The synthesis involved four radiochemical transformations. The key step in the radiosynthesis was the conversion of the 7-[<sup>14</sup>C]-cyano-heptanoic acid benzyloxyamide <b>[</b><sup><b>14</b></sup><b>C]-4</b> directly into the carboxylic acid derivative, 7-benzyloxycarbamoyl-[<sup>14</sup>C]-heptanoic acid <b>[</b><sup><b>14</b></sup><b>C]-8</b> using nitrilase-113 biocatalyst. The final step involved deprotection of the benzyloxy group using catalytic hydrogenation to facilitate the release of the hydroxamic acid without cleaving the phenoxy ester. <b>[</b><sup><b>14</b></sup><b>C]-SHP-141</b> was isolated with a radiochemical purity of 90% and a specific activity of 190 μCi/mg from four radiochemical steps starting from potassium [<sup>14</sup>C]-cyanide in a radiochemical yield of 45%.</p>","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4026","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

A strategy has been developed for the carbon-14 radiosynthesis of [14C]-SHP-141, a 4-(7-hydroxycarbamoyl-heptanoyloxy)-benzoic acid methyl ester derivative containing a terminal hydroxamic acid. The synthesis involved four radiochemical transformations. The key step in the radiosynthesis was the conversion of the 7-[14C]-cyano-heptanoic acid benzyloxyamide [14C]-4 directly into the carboxylic acid derivative, 7-benzyloxycarbamoyl-[14C]-heptanoic acid [14C]-8 using nitrilase-113 biocatalyst. The final step involved deprotection of the benzyloxy group using catalytic hydrogenation to facilitate the release of the hydroxamic acid without cleaving the phenoxy ester. [14C]-SHP-141 was isolated with a radiochemical purity of 90% and a specific activity of 190 μCi/mg from four radiochemical steps starting from potassium [14C]-cyanide in a radiochemical yield of 45%.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
腈水解酶介导的碳-14腈温和水解用于放射合成4-(7-羟基氨基甲酰基-[1-14C-庚酰基]-氧基)-苯甲酸甲酯[14C]-SHP-141:一种新型I/II类组蛋白脱乙酰酶(HDAC)抑制剂
已经开发了一种碳-14放射合成[14C]-SHP-141的策略,这是一种含有末端异羟肟酸的4-(7-羟基氨基甲酰基-庚酰氧基)-苯甲酸甲酯衍生物。合成过程包括四次放射化学转化。放射合成的关键步骤是使用腈酶-13生物催化剂将7-[14C]-氰基庚酸苄氧基酰胺[14C]-4直接转化为羧酸衍生物7-苄氧基氨基-[14C]-庚酸[14C]-8。最后一步涉及使用催化氢化对苄氧基进行脱保护,以促进异羟肟酸的释放而不裂解苯氧基酯。[14C]-SHP-141的放射化学纯度为90%,比活性为190 μCi/mg,从[14C]-氰化钾开始的四个放射化学步骤,放射化学产率为45%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
57
审稿时长
1 months
期刊介绍: The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.
期刊最新文献
Issue Information Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD-L1 Expression In Vivo Issue Information Abstracts From the 29th International Isotope Society UK Meeting 17th November 2023 Lead-212/Bismuth-212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1